Critical care issues: Portopulmonary hypertension

Liver Transplantation

Volumn 6, Issue 4 SUPPL. 1, 2000, Pages

  Mandell, M S ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; VASODILATOR AGENT;

ALGORITHM; CONFERENCE PAPER; DIAGNOSTIC APPROACH ROUTE; ECHOCARDIOGRAPHY; HEPATOPULMONARY SYNDROME; HUMAN; LIVER TRANSPLANTATION; LUNG BLOOD VESSEL; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT INDICATION;

EID: 0033931018     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.500060509     Document Type: Conference Paper

References (52)

1. Conference summary: Biology and pathobiology of the lung Circulation
2. The main functions of the pulmonary circulation
3. Pulmonary circulation and systemic circulation: Similar problems, different solutions
4. Functional recruitment of pulmonary capillaries
5. Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences
6. Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis
7. Pulmonary hemodynamics and gas exchange during exercise in liver cirrhosis
8. Hypoxic pulmonary vasoconstriction in liver cirrhosis
9. Primary pulmonary hypertesion. A national prospective study
10. Primary pulmonary hypertension. ACCP consensus statement
11. Pulmonary arterial hypertension in portal hypertension
12. Pulmonary hypertension complicating portal hypertension
13. Persistence of portosystemic collaterals and splenomegaly on CT after orthotopic liver transplantation
14. Pulmonary hypertension associated with cirrhosis of the liver and with portocaval shunts
15. Primary pulmonary hypertension developing 11 years after a splenorenal shunt for portal hypertension in hepatic cirrhosis
16. Progressive pulmonary hypertension following liver transplantation
17. Formation of a national database on pulmonary hypertension and hepatobiliary disease in chronic liver disease
18. Frequency and clinical implication of increased pulmonary artery pressures in liver transplant patients
19. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension
20. Pathophysiology of pulmonary hypertension. A role for endothelial dysfunction
21. Regulatory functions of the vascular endothelium
22. The role of thrombosis in severe pulmonary hypertension
23. The histopathology of primary pulmonary hypertension
24. Coexistent pulmonary and portal hypertension. Morphological and clinical features
25. Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis
26. Protein C-kinase regulates cytokine-induced tissue factor transcription and procoagulant activity in human endothelial cells
27. Tumor necrosis factor suppresses the transcription of the thrombomodulin gene in endothelial cells
28. Effects of blood flow on thrombin generation is dependent on the nature of the thrombogenic surface
29. Platelet factors predisposing to arterial thrombosis
30. Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics
31. Pulmonary hypertension complicating portal hypertension. Findings on chest radiographs
32. Association between primary pulmonary hypertension and portal hypertension: Analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations
33. Perfusion lung scans provide a guide to which patients with apparent primary pulmonary hypertension merit angiography
34. Electrocardiogram in primary pulmonary hypertension
35. Noninvasive detection of pulmonary hypertension
36. Pulmonary hypertension and liver disease
37. Severe pulmonary hypertension in liver transplant candidates
38. Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: Guidelines for determining a pulmonary vasodilator response
39. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on primary pulmonary hypertension
40. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension
41. Nitric oxide reduces pulmonary hypertension during hepatic transplantation
42. Treatment of pulmonary hypertension with inhaled nitric oxide during hepatic transplantation in an adolescent: Re versibility of pulmonary hypertension after transplantation
43. Nitric oxide does not reverse pulmonary hypertension associated with end-stage liver disease: A preliminary report
44. Combined lung and liver transplantation in patients with cystic fibrosis
45. Single-lung versus liver transplantation for the treatment of portopulmonary hypertension - A comparison of two patients
46. Forum on critical care issues in liver transplantation: Cardiopulmonary concern: Pulmonary hypertension
47. Circulatory pathophysiology and options in hemodynamic management during adult liver transplantation
48. Pulmonary artery hypertension complicating anesthesia for liver transplantation
49. Resolution of pulmonary hypertension after liver transplantation
50. Pulmonary hypertension in a patient undergoing liver transplantation
51. Moderate primary pulmonary hypertension in patients undergoing liver transplantation
52. The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol